Option chain shows key data for GigCapital7's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for GigCapital7.

GigCapital7 (NASDAQ:GIGGU) Stock, Option Chain

GigCapital7 Corp is a Private-to-Public Equity (PPE) company, also known as a blank check company or special purpose acquisition company.

GigCapital7 Corp

B of A Securities analyst Peter Henderson maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Buy and raises the price target from $149 to $175.

News

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Live Nation Entertainment, Raises Price Target to $175

Mr. Doogue's ascension to CEO comes after 27 years of rising through the leadership ranks at Allegro, during which time he enabled many of Allegro's disruptive technologies, originally as an engineer and later as a business leader. Immediately prior to this promotion, Mr. Doogue served as Allegro's Executive Vice President and its first Chief Technology Officer (CTO), leading technology development and worldwide operations, which includes manufacturing, procurement, and quality. Mr. Doogue also previously served as the Company's Senior Vice President of Technology and Products, which included direct oversight of each of the Company's business units. As a testament to his roots as an engineer and technology innovator, Mr. Doogue personally holds 75 semiconductor-related U.S. patents.

ALGM

Allegro MicroSystems Names Mike Doogue As Chief Executive Officer

B of A Securities analyst John Murphy downgrades Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) from Neutral to Underperform and lowers the price target from $13 to $10.

Downgrades

RIVN

B of A Securities Downgrades Rivian Automotive to Underperform, Lowers Price Target to $10

IVVD

Invivyd Says FDA Declined Its Request To Expand Existing Emergency Use Authorization Of PEMGARDA To Include Treatment Of Mild-to-moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $185 price target.

Reiteration

NBIX

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D).
&nbsp;
Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways. Tregs are known to play a key role in the pathogenesis of T1D.1
Under the agreement, TrialNet will conduct the Phase 2 randomized, double-blind, placebo-controlled, clinical trial to investigate the safety and potential efficacy of rezpegaldesleukin in approximately 70 adults and children with new onset stage 3 T1D. Nektar will supply rezpegaldesleukin for the trial and will provide support for the study, including pharmacokinetic and other analyses. Nektar will retain all rights to the rezpegaldesleukin program under the collaboration.

NKTR

Nektar Therapeutics and TrialNet Partner to Study Rezpegaldesleukin for Type 1 Diabetes

Biotech

Earnings

Guidance

Health Care

General

BCRX

Biocryst Pharmaceuticals Expects To Approach Quarterly Positive EPS And Positive Cash Flow In The Second Half Of 2025, And To Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026

Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has reportedly begun to cancel leases for a significant portion of its AI data center capacity in the United States, as per a recent report by TD Cowen.
What Happened: TD Cowen disclosed on Friday that Microsoft has nullified leases equivalent to &#8220;a couple of hundred megawatts&#8221; of capacity, <a href="https://www.bloomberg.com/news/articles/2025-02-24/microsoft-cancels-leases-for-ai-data-centers-analyst-says">Bloomberg</a> reported on Monday. Additionally, the tech giant has also ceased the conversion of so-called statements of qualifications, which usually lead to formal leases. This strategy is reminiscent of tactics previously employed by competitors like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) when they decided to reduce capital expenditure.
TD Cowen&#8217;s report also hints at Microsoft&#8217;s gradual retreat from data center construction and acquisition.&nbsp;The report indicates that Microsoft has let agreements totaling over a gigawatt at larger sites expire and has withdrawn from several deals, each involving approximately 100 megawatts.
SEE ALSO: <a href="https://www.benzinga.com/news/25/02/43901332/biggest-cage-match-ever-mark-cuban-warns-of-a-coming-clash-says-musks-ai-implementation-will-directly-challenge-trumps-grip-on-control">&#8216;Biggest Cage Match Ever&#8217;—Mark Cuban Warns Of A Coming Clash, Says Musk&#8217;s AI Implementation Will Directly Challenge Trump&#8217;s Grip On Control</a>
Why It Matters: This development comes unexpectedly as in January, Microsoft announced its plans to invest around $80 billion in developing AI-powered data centers and deploying AI and cloud-based applications globally. Microsoft&#8217;s possible reduction in spending and data center construction sparks concerns about whether the company is becoming more cautious about future demand.
According to TD Cowen&#8217;s analysts, these changes may suggest that Microsoft is potentially facing an oversupply situation. They also speculated that Microsoft&#8217;s partnership with OpenAI could be shifting in ways that&nbsp;mean the software giant won&#8217;t need the same level of investments. The analysts, however, stated that they are awaiting more details on this.
In January,&nbsp;<a href="https://www.benzinga.com/25/01/42806852/microsoft-pauses-construction-on-33-billion-mount-pleasant-data-center-project-cites-technology-changes-and-design-re-evaluation">Microsoft paused construction</a>&nbsp;on parts of its ambitious data center project in Mount Pleasant, citing changes in technology and design re-evaluation. This move, coupled with the recent lease cancellations, could signal a shift in Microsoft&#8217;s data center strategy.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/equities/25/02/43905646/nvidia-set-for-clear-beat-and-raise-special-as-ai-demand-surges-says-dan-ives">Nvidia Set For &#8216;Clear Beat And Raise Special&#8217; As AI Demand Surges, Says Dan Ives</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>

Markets

Tech

MSFT

Microsoft Pulls Plug On AI Data Center Leases, Says Analyst: Oversupply Situation Likely

AN2 Selects QOL-B as New Phase 3 Primary Efficacy Endpoint
Goal to Accelerate Unblinding Phase 3 Data in Q2 2025 Ahead of Potential FDA Meeting

ANTX

AN2 Therapeutics Advances Phase 3 EBO-301 Trial Wih PRO-Based QOL-B Endpoint, Setting Stage For Potential Registrational Pathways

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will refresh its more premium car offerings- the Model S and Model X- later this year, senior company executive Lars Moravy said in an interview published on Sunday.
What Happened:&nbsp;Moravy, in an interview with&nbsp;Ryan McCaffrey&nbsp;recorded on Feb.13 and published on Sunday,&nbsp;said that the company intends to show its Model S and X vehicles &#8220;some love&#8221; and refresh them later this year.
Tesla last refreshed the Model S and X in 2021. 
In the past two years, the company has focussed on refreshing its cheaper, mass-market offerings. 
Tesla launched a&nbsp;<a href="https://www.benzinga.com/news/24/02/36921718/youtuber-marques-brownlee-reviews-refreshed-model-3-calls-it-teslas-most-important-car-i-am-impresse" target="_blank" rel="noreferrer noopener">refreshed Model 3 in Aug. 2023&nbsp;</a>in China and in the U.S. months later in January 2024. In January this year, the company also launched a <a href="https://www.benzinga.com/25/02/43772576/tesla-to-start-delivering-shanghai-made-refreshed-model-ys-next-week">refreshed version of its best-selling Model Y SUV. </a>
Moravy said that the company focussed on refreshing the Model 3 and Y first as they are higher volume vehicles and refreshing them was needed for the company to stay competitive. However, the S and X are not going anywhere anytime soon, Moravy said.
&#8220;As Elon says, we definitely there&#8217;s some nostalgia to them and like keeping them around and like we don&#8217;t have any immediate plans to change that,&#8221; he said.
Why It Matters: The refreshes come amid concerns about an aging car lineup. Tesla&#8217;s latest offering is its Cybertruck which it started delivering in Nov. 2023. The vehicle, however, is a truck and caters to a different customer demographic. 
The latest car from Tesla is the Model Y SUV, whose production the company started in January 2020. 
The Model X, however, is Tesla&#8217;s <a href="https://www.benzinga.com/tech/24/12/42496103/teslas-model-s-model-x-and-cybertruck-now-have-the-same-starting-price-which-to-buy">priciest offering in the U.S</a>. The base version of the Model X starts at $84,990, pricier than even the Cybertruck or Model S whose base versions start at $79,990.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43905539/elon-musk-led-spacex-to-undertake-starships-8th-test-flight-on-friday" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s SpaceX To Undertake Starship&#8217;s 8th Test Flight On Friday</a></li>
<li></li>
</ul>
Image via Tesla

TSLA

Tesla To Launch Refreshed Model S, X Later This Year, Says Senior Exec

Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet&#xAE; device, today announced that it has entered into an amendment to its outstanding senior secured convertible debt due November 1, 2025 (the "Amendment").The Amendment defers the Company's monthly interest and amortization payments from March 2025 through September 2025. Additionally, the Amendment allows the full conversion of the debt into common shares of the Company commencing on April 1, 2025, at a price of $1.68 per share.

EYEN

Eyenovia Allows Full Debt Conversion to Common Shares at $1.68 Starting April 2025, Defers Payments Until September 2025

B of A Securities analyst Steve Byrne upgrades CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) from Underperform to Neutral and maintains the price target from $84 to $84.

Upgrades

B of A Securities Upgrades CF Industries Holdings to Neutral, Maintains Price Target to $84

The company has received the "Day 74" notification from the FDA acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review.&nbsp;

GKOS

Glaukos Secures FDA Acceptance Of NDA Submission For Epioxa

Ceragon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>),&nbsp;a leading solutions provider of end-to-end wireless connectivity, today announced the launch of its new innovative, next-gen products: IP-100E, IP-50GP, and EtherHaul 8020FX at Mobile World Congress (MWC) 2025.
&nbsp;
With customers' needs always in mind, Ceragon is unveiling new innovations that will expand its end-to-end offering to both its core business and private networks business worldwide.
<ul>
<li>The IP-100E, powered by&nbsp;Ceragon's in-house proprietary system-on-a-chip, is an innovative, dual-carrier, E-band solution, delivering a game-changing 25 Gbps from one box, and up to 40 Gbps in a 4+0 all-outdoor link.</li>
<li>The IP-50GP, Ceragon's latest split-mount microwave solution, offers a cost-optimized approach to achieving seamless connectivity, and is designed to meet the demands of modern networks, delivering optimal performance without compromising on budget.</li>
<li>Ceragon's EtherHaul 8020FX, a millimeter-wave backhaul solution, offers exceptional ease of installation and operations, cost efficiency, and high capacity — a must-see for anyone tackling demanding backhaul challenges.</li>
</ul>
In addition to the above products, Ceragon's IP-50EX mmW series also features a new model — the IP-50EXA — which offers the best price-performance ratio available in the industry and is already gaining significant traction in the market.
At MWC, Ceragon will also showcase its software and service offerings, including its cutting-edge Network Digital Twin, Smart Activation Key, and an interesting mix of use cases that illustrate how Ceragon enables private network operators to tackle diverse connectivity challenges with tailored, end-to-end solutions.

CRNT

Ceragon Unveils Next-Gen Wireless Connectivity Solutions at MWC 2025, Expanding End-to-End Offerings

Financial Outlook for 2025
Based on the early signs we are seeing that many more of our Medicare patients are able to afford paid therapy in 2025, and the strong patient demand for ORLADEYO to start the year, the company has increased its full year 2025 outlook for global net ORLADEYO revenue to between $535 million and $550 million (previously $515 million to $535 million). The company now expects full year 2025 total revenue (including RAPIVAB (peramivir injection)) will be between $560 million and $575 million (previously $540 million to $560 million).
The increased guidance for ORLADEYO revenues in 2025 also results in an increase in related operating expenses, primarily related to cost of goods sold, distribution costs and higher incentive compensation. The company reiterates the previously provided 2025 non-GAAP operating expense outlook range of $425 million to $435 million (not including stock-based compensation). The revenue related operating expense increases are captured at the higher end of this range.

BioCryst Pharmaceuticals Expects Full Year 2025 Total Revenue Of $560M-$575M Compared To Prior Guidance Of $540M-$560M And Consensus Of 545.31M, The Company Increased Its 2025 Outlook For Global Net Orladeyo Revenue To Between $535M-$550M, Previously $515M-$535M

SYTA

Siyata Mobile Announces New Agreement With IP Access International, Expanding Distribution

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S).

VNDA

Vanda Pharmaceuticals Unveils Potential ASO Treatment for Rare Nerve Disease Charcot-Marie-Tooth Type 2S

The acquisition is expected to close in the first quarter of 2025 and is subject to regulatory approval in Austria and customary closing conditions. Dow Jones's parent company, News Corp, expects to receive a $4 million tax benefit in connection with the transaction.

NOTE

NWSA

Dow Jones Agrees To Acquire Dragonfly Intelligence And Oxford Analytica From FiscalNote For $40M

Unity Software Inc. ("Unity") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>), the leading platform to create and grow games and interactive experiences, today announced its intent to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2030 (the "Notes") in a private placement (the "Offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Unity also intends to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $75.0 million aggregate principal amount of Notes.
The Notes will be general unsecured obligations of Unity and will accrue interest payable semiannually in arrears. Upon conversion, Unity will pay or deliver, as the case may be, cash, shares of Unity's common stock or a combination of cash and shares of Unity's common stock, at its election. The interest rate, initial conversion rate and other terms of the Notes will be determined at the time of pricing of the Offering.
Unity expects to use the net proceeds from the Offering to pay the cost of the capped call transactions described below and, together with cash on hand, if necessary, to repurchase for cash approximately, subject to market conditions, $500.0 million in aggregate principal amount of its 0% Convertible Senior Notes due 2026 (the "2026 Notes") in the Note Repurchase Transactions (as described below). If the initial purchasers exercise their option to purchase additional Notes, Unity expects to use a portion of the net proceeds from the sale of the additional Notes to enter into additional capped call transactions. Unity expects to use any remaining net proceeds from the Offering for general corporate purposes, which may include additional repurchases of the 2026 Notes from time to time following the Offering, and acquisitions or strategic investments in complementary businesses or technologies (although Unity does not currently have any plans for any such acquisitions or investments), working capital, operating expenses and capital expenditures.

Offerings

Unity Announces $500M Convertible Senior Notes Offering, Plans Debt Repurchase and Strategic Investments

B of A Securities analyst Peter Galbo initiates coverage on Smithfield Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFD#NASDAQ">SFD</a>) with a Buy rating and announces Price Target of $28.

Comments

GigCapital7

GigCapital7 (GIGGU) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga